352 related articles for article (PubMed ID: 31287855)
1. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease.
Bauman LE; Xiong Y; Mizuno T; Minar P; Fukuda T; Dong M; Rosen MJ; Vinks AA
Inflamm Bowel Dis; 2020 Feb; 26(3):429-439. PubMed ID: 31287855
[TBL] [Abstract][Full Text] [Related]
2. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.
Brandse JF; Mould D; Smeekes O; Ashruf Y; Kuin S; Strik A; van den Brink GR; DʼHaens GR
Inflamm Bowel Dis; 2017 Apr; 23(4):650-660. PubMed ID: 28195852
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
[TBL] [Abstract][Full Text] [Related]
4. Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease.
Choi SY; Kang B; Choe YH
Gut Liver; 2019 Sep; 13(5):541-548. PubMed ID: 30970435
[TBL] [Abstract][Full Text] [Related]
5. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease.
Vermeire S; Dubinsky MC; Rabizadeh S; Panetta JC; Spencer EA; Dreesen E; D'Haens G; Dervieux T; Laharie D
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102374. PubMed ID: 38750934
[TBL] [Abstract][Full Text] [Related]
6. Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment.
Rolandsdotter H; Marits P; Sundin U; Wikström AC; Fagerberg UL; Finkel Y; Eberhardson M
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272355
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study.
Funk RS; Shakhnovich V; Cho YK; Polireddy K; Jausurawong T; Gress K; Becker ML
Pediatr Rheumatol Online J; 2021 May; 19(1):62. PubMed ID: 33933127
[TBL] [Abstract][Full Text] [Related]
8. Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy.
van Hoeve K; Seyed Tabib NS; Dreesen E; Tops S; Hoffman I; Gils A; Ferrante M; Vermeire S
J Pediatr; 2022 Jan; 240():150-157.e4. PubMed ID: 34481805
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.
Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
Aliment Pharmacol Ther; 2015 Sep; 42(5):529-39. PubMed ID: 26113313
[TBL] [Abstract][Full Text] [Related]
10. Serum infliximab concentrations in pediatric inflammatory bowel disease.
Hämäläinen A; Sipponen T; Kolho KL
Scand J Gastroenterol; 2013 Jan; 48(1):35-41. PubMed ID: 23148710
[TBL] [Abstract][Full Text] [Related]
11. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease.
Piester T; Frymoyer A; Christofferson M; Yu H; Bass D; Park KT
Inflamm Bowel Dis; 2018 Jan; 24(2):227-234. PubMed ID: 29361094
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
13. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study.
Dotan I; Ron Y; Yanai H; Becker S; Fishman S; Yahav L; Ben Yehoyada M; Mould DR
Inflamm Bowel Dis; 2014 Dec; 20(12):2247-59. PubMed ID: 25358062
[TBL] [Abstract][Full Text] [Related]
14. Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease.
Xiong Y; Mizuno T; Colman R; Hyams J; Noe JD; Boyle B; Tsai YT; Dong M; Jackson K; Punt N; Rosen MJ; Denson LA; Vinks AA; Minar P
Clin Pharmacol Ther; 2021 Jun; 109(6):1639-1647. PubMed ID: 33354765
[TBL] [Abstract][Full Text] [Related]
15. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
Merras-Salmio L; Kolho KL
J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
[TBL] [Abstract][Full Text] [Related]
16. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
[TBL] [Abstract][Full Text] [Related]
17. Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study.
Naviglio S; Lacorte D; Lucafò M; Cifù A; Favretto D; Cuzzoni E; Silvestri T; Pozzi Mucelli M; Radillo O; Decorti G; Fabris M; Bramuzzo M; Taddio A; Stocco G; Alvisi P; Ventura A; Martelossi S
J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):37-44. PubMed ID: 30211845
[TBL] [Abstract][Full Text] [Related]
18. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients.
Dubinsky MC; Phan BL; Singh N; Rabizadeh S; Mould DR
AAPS J; 2017 Jan; 19(1):215-222. PubMed ID: 27739008
[TBL] [Abstract][Full Text] [Related]
20. Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.
Zitomersky N; Chi L; Liu E; Bray KR; Papamichael K; Cheifetz AS; Snapper SB; Bousvaros A; Silvester JA
J Pediatr Gastroenterol Nutr; 2024 Feb; 78(2):261-271. PubMed ID: 38374555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]